ArticleFrontiers in aging neuroscience2026
Pericarotid fat density: a novel predictor of cognitive and functional outcomes in cerebral small vessel disease.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pericarotid fat density (PFD) obtained by computed tomography angiography (CTA) could serve as a surrogate biomarker reflecting local inflammation. The study aimed to quantitatively estimate the impact of PFD on cognitive and functional outcomes in patients with cerebral small vessel disease (CSVD). Methods: A total of 71 symptomatic and 55 asymptomatic CSVD patients were prospectively recruited. Imaging characteristics comprising CSVD markers and carotid artery markers (PFD values, calcification, stenosis degree, ulceration, and maximum wall thickness) were analyzed. Cognitive assessments were performed 90 days after acute infarcts, including diverse neuropsychological scales (the Montreal Cognitive Assessment, the Shape Trail Test, the Stroop test, and the Rey-Osterrieth Complex Figure Test) and sensitive event-related potential (ERP) detection. Worse functional outcomes were defined as a Modified Rankin Scale change score (ΔmRS) ≥ 0 (ΔmRS = mRS Results: Symptomatic CSVD showed significantly higher PFD values than asymptomatic CSVD. As indicated by multiple scales and P3a/P3b amplitude, cognitive function in symptomatic CSVD was poorer than that in asymptomatic CSVD. Symptomatic CSVD showed numerically stronger correlations between PFD values and cognitive impairment, with more parameters involved and the strongest correlations existing among ERP data. Maximum PFD was identified as an independent predictor of adverse functional outcomes ( Conclusion: The increased PFD values were closely associated with cognitive impairment and adverse functional outcomes in CSVD patients, especially among those with symptoms. Our findings could assist in the risk stratification and tailored treatment of CSVD patients to facilitate prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.